PURE Bioscience Sponsors and Exhibits at the North American Meat Processors Association E. coli Prevention Conference

PURE Bioscience, Inc. (NASDAQ:PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, is sponsoring and exhibiting at the North American Meat Processors Association E. coli Prevention Conference being held this week in Chicago where Charles Deibel of Deibel Laboratories presented preliminary data on use of SDC in beef processing.

Tom Myers, PURE Bioscience’s Executive Vice President, Sales and Marketing, stated, "We’ve recognized that the FDA is moving toward regulating not only E. coli O157 but also the six other shiga toxin-producing E. coli bacteria, and are pleased to report that Deibel’s research demonstrates that PURE Hard Surface performs just as well on other E. coli serotypes as it does on O157. Even more exciting was the data presented by Deibel showing that SDC demonstrates significant reductions of E. coli on beef trim as a spray and a dip as well as when incorporated into ground beef. This new data, combined with our existing GRAS determination, forms the proof-of-concept foundation for proceeding with our GRAS determination project for SDC as a direct food contact aid and as a preservative for beef.”

The new studies build on PURE’s recent announcement of GRAS (generally recognized as safe) determination for SDC as a contact biocide in food processing, which set the stage for additional GRAS projects as an indirect and direct food additive in food processing.

Charles Deibel, President, Deibel Laboratories, said, "Given the results of the testing Deibel Laboratories performed on the shiga toxin producing E.coli serotypes and the pathogen log reductions in the direct application of SDC to beef trim and ground beef, we believe the SDC molecule will be a truly unique tool to help eliminate the dangerous pathogens that have plagued the food industry for years."

Deibel Laboratories is a leading international microbiology, chemistry and consulting company serving the food production and personal care industries.

About PURE Hard Surface

U.S. EPA-registered PURE Hard Surface disinfectant and food contact surface sanitizer provides an unparalleled combination of high efficacy and low toxicity with 30-second bacterial and viral kill times and 24-hour residual protection. PURE Hard Surface completely kills hazardous food pathogens such as E. coli, Salmonella and Campylobacter, and its active ingredient, SDC, has been determined Generally Recognized as Safe (GRAS) for use as a biocide on food processing equipment, machinery and utensils. PURE Hard Surface eliminates resistant pathogens like MRSA and Carbapenem-resistant Klebsiella pneumoniae (NDM-1) as well as dangerous fungi and viruses including HIV, Hepatitis B, Hepatitis C, Norovirus, Influenza A, Avian Influenza and H1N1. PURE Hard Surface delivers this powerful broad-spectrum efficacy while remaining classified as least-toxic (Category IV) by the US EPA.

About PURE Bioscience, Inc.

PURE Bioscience, Inc. develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE’s proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today’s global trend toward industry and consumer use of "green” products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver, which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project,” "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s cash position and liquidity requirements, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.